Pipeline news

• Hydrogel corneal inlay improves near, intermediate, distance vision at 3 months

  17 February 2014 Matt Hasson / Healio Ophthalmology

  

  A hydrogel corneal inlay improved near, intermediate and distance vision, regardless of preoperative refractive error, according to a study presented at Hawaiian Eye 2014.

• Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

  03 February 2014

  

  Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center.

• Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management

  13 January 2014

  

  Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer.

• Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

  03 November 2013

  

  Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.

• ReVision Optics – 2013 Fierce 15

  21 October 2013 FierceMedicalDevices

  

  ReVision Optics is upping the technological game with vision improvement devices and technology. The company's Raindrop Near Vision microscopic hydrogel inlay is designed to treat patients with presbyopia, the loss of near vision in patients when they reach middle age and typically need reading glasses. CEO John Kilcoyne said doctors can now also use RainDrop in patients receiving a separate procedure to correct their distance vision.

• FierceMedicalDevices' 2013 Fierce 15

  21 October 2013 Mark Hollmer, FierceMedicalDevices

  This year's crop endured the struggles many startups face and came out ahead. They've attracted substantial funding from major investors in a tough market, proving the worth of their products. Many are also already in--or close to--market with their signature products, a sign of stability that draws investor commitments much more these days than companies on the earlier side of development.

• Hydrogel inlay improves uncorrected near visual acuity in presbyopic emmetropic eyes

  26 September 2013 Matt Hasson, Ocular Surgery News U.S. Edition

  The inlay creates multifocality at the corneal plane, with near vision on the visual axis and a transition to intermediate, distance vision out to the periphery.

• Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries

  05 September 2013

  

  Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions.

• Corneal inlays have the potential to 'treat millions'

  30 June 2013 Michelle Dalton, EyeWorld

  Corneal inlays are designed to treat presbyopia by being inserted in the non-dominant eye and correcting for near vision; distance vision remains (mostly) unaffected.

• Nanotechnology Didn't Shrink and Disappear; In Fact, It's Everywhere

  04 February 2013 Nick Rockel, Institutional Investor

  Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.